SCIENTIFIC PROGRAMME
Thursday, March 21, 2024
08.30 Registration Opens
09.30 - 09.40 Welcome Address
Michael von Bergwelt, Munich, Germany
09.40 - 11.10 Plenary Session 1: Basic Tumor Immunology
09.40 - 10.10
01.01. Tissue resident macrophages and cancer
Julie Helft, Paris, France
10.10 - 10.40
01.02. Nociception and cancer immunosurveillance
Sebastien Talbot, Kingston, ON, Canada
10.40 - 11.10
01.03. Deregulated heme metabolism in T cell exhaustion
Ping-Chih Ho, Lausanne, Switzerland
11.10 - 11.40 Coffee Break
11.40 - 13.10 Plenary Session 2: New Targets and New Leads
11.40 - 12.10
02.01. Type I IFN , DC and anti-tumor immunity
Stefani Spranger, Boston, MA, USA
12.10 - 12.40
02.02. Immunocytokines
Dario Neri, Zurich, Switzerland
12.40 - 13.10
02.03. Targeting TBK1 to overcome resistance to immunotherapy
Russel W. Jenkins, Boston, MA, USA
13.10 - 13.40 Satellite Symposium
13.40 - 15.00 Lunch & Poster Viewing
15.00 - 17.00 Plenary Session 3: Exploiting B Cells and Other Cell Types
15.00 - 15.30
03.01. The role of TLS in the response to IO agents
15.30 - 16.00
03.02. iPSC-derived strategies for cancer immunotherapy
Maria Themeli, Amsterdam, The Netherlands
16.00 - 16.30
03.03. Targeting myeloid cells to overcome resistance to cancer immunotherapy
16.30 - 16.45 03.04. Speaker 4 – proffered paper
16.45 - 17.00 03.05. Speaker 5 – proffered paper
17.00 - 18.00 Plenary Session 4: ITOC10 Keynote Lecture
04.01. The role of the Homo sapiens in the emergence and the management of the climate crisis
Dr. Philipp Blom, Vienna, Austria
18.00 - 20.00 Networking Event and Poster Viewing (at the venue)
Friday, March 22, 2024
08.30 – 09.30 Plenary Session 5: Microbiome
08.30 – 09.00
05.01. Microbiota modulation of cancer immunotherapy
Lisa Derosa, Villejuif, France
09.00 – 09.30
05.02. Impact of microbiome on CAR T cell efficacy
Christoph Stein-Thöringer, Tübingen, Germany
09.30 – 10.30 Plenary Session 6: Pro & Contra Sessions: Adjuvant vs Neoadjuvant IO Treatment
09.30 – 10.00
06.01. Pro-Adjuvant
Alexander Eggermont, Utrecht, The Netherlands
10.00 – 10.30
06.02. Pro-Neoadjuvant
Christian Blank, Leiden, The Netherlands
10.30 – 11.00 Coffee Break
11.10 – 12.30 Plenary Session 7: Combination Therapies
11.00 – 11.30
07.01. Intradermal CpG/tilsotolimod treatment in pT3-4 cN0M0 melanoma: efficacy update of the randomized INTRIM trial
Tanja de Gruijl, Amsterdam, The Netherlands
11.30 – 12.00
07.02. Tuning bispecific antibody application and rationale combinations for optimal therapies
Marion Subklewe, Munich, Germany
12.00 – 12.15 07.03. Speaker 3 – proffered paper
12.15 – 12.30 07.04. Speaker 4 – proffered paper
12.30 - 13.00 Satellite Symposium
13.00 – 14.30 Lunch & Poster Viewing
14.30 – 15.15 Plenary Session 8: ITOC10 Lifetime Achievement Award presented to Prof. Dr. Andrea Schietinger
08.01. Deciphering mechanisms of T cell exhaustion
Andrea Schietinger, New York, NY, USA
15.15 - 16.30 Plenary Session 9: Immuno-Monitoring
15.15 – 15.45
09.01. Multidimensional dissection of tumor-immune interaction
Rebekka Schneider-Kramann, Aachen, Germany
15.45 - 16.15
09.02. CODEXing the TME
Christian Schürch, Tübingen, Germany
16.15 - 16.30 09.03. Speaker 3 – proffered paper
16.30 - 17.00 Coffee Break
17.00 - 18.00 Plenary Session 10: Young Researcher Session (from submitted abstracts)
17.00 - 17.15 10.01. Speaker 1
17.15 - 17.30 10.02. Speaker 2
17.30 – 17.45 10.03. Speaker 3
17.45 – 18.00 10.04. Speaker 4
18.00 - 19.00 Poster Viewing with Presenters
20.00 ITOC10 Conference Dinner
Saturday, March 23, 2024
08.00 – 09.00 Plenary Session 11: Reaching New Grounds in Cellular Therapies
08.00 – 08.30
11.01. CD19 CAR T in B cell driven auto-immune disease
Fabian Müller, Erlangen, Germany
08.30 – 09.00
11.02. TIL have come back of age in Melanoma
Inge Marie Svane, Herlev, Denmark
09.00 – 10.30 Plenary Session 12: Cell therapies in Hematologic Oncology
09.00 – 09.30
12.01. Leveraging metabolites to boost CAR T cell activity in hematology
Hendrik Poeck, Regensburg, Germany
09.30 – 10.00
12.02. Cellular immunotherapy beyond CAR T cells in hematology
Jianzhu Chen, Cambridge, MA, USA
10.00 – 10.30
12.03. New approaches for cellular therapies in AML
Saar Gill, Philadelphia, PA, USA
10.30 – 11.00 Coffee Break
11.00 – 12.30 Plenary Session 13: Cell Therapies in Solid Oncology
11.00 – 11.30
13.01. CAR-T in prostate cancer
Vivek Narayan, Philadelphia, PA, USA
11.30 – 12.00
13.02. Engineering cytokine functionalities in CAR T cells
Saul Priceman, Duarte, CA, USA
12.00 – 12.15 13.03. Speaker 3 – proffered paper
12.15 – 12.30 13.04. Speaker 4 – proffered paper
12.30 – 12.45 13.05. Speaker 5 – proffered paper
12.45 – 13.15 Plenary Session 14: Best Poster Awards & Closing Remarks
13.15 – 14.15 Lunch & Farewell